Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FATE THERAPEUTICS INCFATE · Entity 5968 | Director · President and CEO | August 04, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FATE THERAPEUTICS INC
Report date August 04, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 591,815 |
Reported balance
After 2026-08-04 transaction · row 1
1 source rowRow 1 · 2026-08-04 · Sale · Disposed 43,947 · Balance 591,815 F1: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 75,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person. F2: Represents the weighted average sale price of the shares sold ranging from $2.415 to $2.540 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 75,000 shares of Common Stock underlying RSUs granted to the Reporting Person on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell-to-cover" transactions and were not made at the discretion of the Reporting Person.
F2: Represents the weighted average sale price of the shares sold ranging from $2.415 to $2.540 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2021 Filed Jun 16, 2021 20:26 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,156 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-21-040914 · doc4.xml · derivative · entry 6 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,156 shares Expires 2026-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:26 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 400 | $90.76 | $36,303.00 |
DisclosureSEC source: 0001209191-21-040914 · doc4.xml · nonDerivative · entry 5 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,740 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. F4 · price: Represents the weighted average sale price of the shares sold from $90.71 to $90.86 per share. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:26 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 8,220 | $89.68 | $737,154.80 |
DisclosureSEC source: 0001209191-21-040914 · doc4.xml · nonDerivative · entry 4 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,140 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. F3 · price: Represents the weighted average sale price of the shares sold from $89.45 to $90.16 per share. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:26 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 16,380 | $89.11 | $1,459,587.40 |
DisclosureSEC source: 0001209191-21-040914 · doc4.xml · nonDerivative · entry 3 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,360 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $88.45 to $89.44 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 4. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:26 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 8,844 | $2.73 | $24,144.12 |
DisclosureSEC source: 0001209191-21-040914 · doc4.xml · nonDerivative · entry 2 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:26 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 16,156 | $2.90 | $46,852.40 |
DisclosureSEC source: 0001209191-21-040914 · doc4.xml · nonDerivative · entry 1 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0000899243-21-011920 · doc4.xml · derivative · entry 7 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,156 Underlying: Common Stock · 25,000 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. F7 · derivative.exercise_date: This option is fully vested. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 1,018 | $94.59 | $96,297.10 |
DisclosureSEC source: 0000899243-21-011920 · doc4.xml · nonDerivative · entry 6 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,740 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. F6 · price: Represents the weighted average sale price of the shares sold from $94.40 to $94.90 per share. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 3,205 | $93.75 | $300,460.74 |
DisclosureSEC source: 0000899243-21-011920 · doc4.xml · nonDerivative · entry 5 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,758 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. F5 · price: Represents the weighted average sale price of the shares sold from $93.31 to $94.29 per share. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 8,404 | $92.64 | $778,577.65 |
DisclosureSEC source: 0000899243-21-011920 · doc4.xml · nonDerivative · entry 4 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,963 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. F4 · price: Represents the weighted average sale price of the shares sold from $92.31 to $93.27 per share. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 8,416 | $91.94 | $773,782.19 |
DisclosureSEC source: 0000899243-21-011920 · doc4.xml · nonDerivative · entry 3 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,367 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. F3 · price: Represents the weighted average sale price of the shares sold from $91.30 to $92.29 per share. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 3,957 | $90.89 | $359,654.50 |
DisclosureSEC source: 0000899243-21-011920 · doc4.xml · nonDerivative · entry 2 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,783 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $90.30 to $91.29 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 6. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 25,000 | $2.90 | $72,500.00 |
DisclosureSEC source: 0000899243-21-011920 · doc4.xml · nonDerivative · entry 1 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. F1 · price: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 23:22 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 6,851 | Not disclosed Strike: $109.01 | Not disclosed |
DisclosureSEC source: 0001209191-21-004956 · doc4.xml · derivative · entry 2 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,851 Underlying: Common Stock · 6,851 shares Expires 2031-01-20 F3 · price: Not applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments beginning on February 1, 2021 such that this option is fully exercisable on January 1, 2025. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 23:22 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon stock | 18,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004956 · doc4.xml · nonDerivative · entry 1 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,740 F1 · security: Award of restricted stock units ("RSUs") that vests with respect to the 1/4th of the underlying shares on each of January 8, 2022, January 8, 2023, January 8, 2024, and January 8, 2025. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 01:40 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 871 | $109.65 | $95,508.63 |
DisclosureSEC source: 0001209191-21-003340 · doc4.xml · nonDerivative · entry 7 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,727 F6 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.19 to $110.18 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 01:40 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 1,051 | $110.76 | $116,406.66 |
DisclosureSEC source: 0001209191-21-003340 · doc4.xml · nonDerivative · entry 6 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,598 F6 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.19 to $111.18 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 01:40 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 1,332 | $111.62 | $148,672.51 |
DisclosureSEC source: 0001209191-21-003340 · doc4.xml · nonDerivative · entry 5 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,649 F6 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.19 to $112.18 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 13, 2021 01:40 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 151 | $114.76 | $17,328.01 |
DisclosureSEC source: 0001209191-21-003340 · doc4.xml · nonDerivative · entry 4 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,981 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.38 to $115.37 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 13, 2021 01:40 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 872 | $115.80 | $100,976.73 |
DisclosureSEC source: 0001209191-21-003340 · doc4.xml · nonDerivative · entry 3 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,132 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.38 to $116.37 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 13, 2021 01:40 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 2,451 | $117.15 | $287,144.45 |
DisclosureSEC source: 0001209191-21-003340 · doc4.xml · nonDerivative · entry 2 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,004 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.38 to $117.37 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 13, 2021 01:40 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 2,756 | $117.60 | $324,102.84 |
DisclosureSEC source: 0001209191-21-003340 · doc4.xml · nonDerivative · entry 1 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,455 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.38 to $118.37 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $2.90 | Not disclosed |
DisclosureSEC source: 0001209191-20-063449 · doc4.xml · derivative · entry 10 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,156 Underlying: Common Stock · 25,000 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F10 · price: Not applicable. F9 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 100 | $102.75 | $10,275.00 |
DisclosureSEC source: 0001209191-20-063449 · doc4.xml · nonDerivative · entry 9 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,211 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 1,006 | $102.06 | $102,675.38 |
DisclosureSEC source: 0001209191-20-063449 · doc4.xml · nonDerivative · entry 8 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,311 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F8 · price: Represents the weighted average sale price of shares sold ranging from $101.56 to $102.42 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 400 | $100.97 | $40,388.00 |
DisclosureSEC source: 0001209191-20-063449 · doc4.xml · nonDerivative · entry 7 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,317 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F7 · price: Represents the weighted average sale price of shares sold ranging from $100.48 to $101.41 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 3,822 | $99.77 | $381,315.21 |
DisclosureSEC source: 0001209191-20-063449 · doc4.xml · nonDerivative · entry 6 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,717 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F6 · price: Represents the weighted average sale price of shares sold ranging from $99.28 to $100.25 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 3,148 | $98.80 | $311,012.64 |
DisclosureSEC source: 0001209191-20-063449 · doc4.xml · nonDerivative · entry 5 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,539 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F5 · price: Represents the weighted average sale price of shares sold ranging from $98.28 to $99.26 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 2,946 | $97.70 | $287,812.12 |
DisclosureSEC source: 0001209191-20-063449 · doc4.xml · nonDerivative · entry 4 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,687 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F4 · price: Represents the weighted average sale price of shares sold ranging from $97.27 to $98.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 11,765 | $96.65 | $1,137,141.37 |
DisclosureSEC source: 0001209191-20-063449 · doc4.xml · nonDerivative · entry 3 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,633 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F3 · price: Represents the weighted average sale price of shares sold ranging from $96.23 to $97.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 1,813 | $95.89 | $173,857.09 |
DisclosureSEC source: 0001209191-20-063449 · doc4.xml · nonDerivative · entry 2 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,398 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F2 · price: Represents the weighted average sale price of shares sold ranging from $95.23 to $96.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 25,000 | $2.90 | $72,500.00 |
DisclosureSEC source: 0001209191-20-063449 · doc4.xml · nonDerivative · entry 1 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 21,924 | Not disclosed Strike: $2.90 | Not disclosed |
DisclosureSEC source: 0001209191-20-050683 · doc4.xml · derivative · entry 8 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,156 Underlying: Common Stock · 21,924 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F7 · price: Not applicable. F6 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 3,076 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0001209191-20-050683 · doc4.xml · derivative · entry 7 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,076 shares Expires 2021-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F7 · price: Not applicable. F6 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 600 | $37.49 | $22,494.00 |
DisclosureSEC source: 0001209191-20-050683 · doc4.xml · nonDerivative · entry 6 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,211 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F5 · price: Represents the weighted average sale price of the shares sold ranging from $37.47 to $37.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 7,016 | $36.93 | $259,084.74 |
DisclosureSEC source: 0001209191-20-050683 · doc4.xml · nonDerivative · entry 5 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,811 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $36.47 to $37.45 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 16,784 | $36.03 | $604,653.67 |
DisclosureSEC source: 0001209191-20-050683 · doc4.xml · nonDerivative · entry 4 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,827 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $35.47 to $36.46 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 600 | $34.65 | $20,791.98 |
DisclosureSEC source: 0001209191-20-050683 · doc4.xml · nonDerivative · entry 3 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,611 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $34.26 to $35.05 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 21,924 | $2.90 | $63,579.60 |
DisclosureSEC source: 0001209191-20-050683 · doc4.xml · nonDerivative · entry 2 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 3,076 | $1.69 | $5,198.44 |
DisclosureSEC source: 0001209191-20-050683 · doc4.xml · nonDerivative · entry 1 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 1,153 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0001209191-20-006263 · doc4.xml · derivative · entry 2 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,153 shares Expires 2020-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 1,153 | $1.69 | $1,948.57 |
DisclosureSEC source: 0001209191-20-006263 · doc4.xml · nonDerivative · entry 1 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $21.99 | Not disclosed |
DisclosureSEC source: 0001209191-20-003027 · doc4.xml · derivative · entry 3 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2030-01-08 F5 · price: Not applicable. F4 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 1, 2020 such that this option is fully exercisable on January 1, 2024. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 5,700 | $20.69 | $117,947.25 |
DisclosureSEC source: 0001209191-20-003027 · doc4.xml · nonDerivative · entry 2 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,058 F2 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 15,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election on November 21, 2019 by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.41 to $20.88 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-003027 · doc4.xml · nonDerivative · entry 1 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,758 F1 · security: Award of restricted stock units ("RSUs") that vests with respect to 1/4 of the underlying shares on each of January 8, 2021, January 8, 2022, January 8, 2023, and January 8, 2024. This grant is subject to an accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer. Read SEC document |
| October 15, 2019 Filed Oct 16, 2019 20:06 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 6,200 | $14.18 | $87,890.58 |
DisclosureSEC source: 0001209191-19-053277 · doc4.xml · nonDerivative · entry 1 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,758 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 17,500 shares of Common Stock underlying restricted stock units ("RSUs") granted to the reporting person on October 15, 2015. This sale was made pursuant to an irrevocable election on December 18, 2018 by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.94 to $14.35 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: All remaining shares of Common Stock held by the reporting person are subject to the terms of a lock-up agreement with Jefferies LLC and Citigroup Global Markets Inc. (the "Representatives"), as representatives of the underwriters in the Company's public offering pursuant to a prospectus supplement dated September 11, 2019, pursuant to which the reporting person agreed, without the prior written consent of the Representatives, and subject to limited exceptions, not to sell, offer to sell, contract to sell or lend, effect any short sale, pledge, hypothecate or grant any security interest in, or otherwise transfer or dispose of, any shares of Common Stock, either directly or indirectly. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 135,000 | Not disclosed Strike: $16.55 | Not disclosed |
DisclosureSEC source: 0001209191-19-003022 · doc4.xml · derivative · entry 2 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2029-01-06 F3 · price: Not applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 1, 2019 such that this option is fully exercisable on January 1, 2023. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-003022 · doc4.xml · nonDerivative · entry 1 Valamehr Bahram · CIK 0001748177 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,958 F1 · security: Award of Restricted Stock Units that vests with respect to 1/3 of the underlying shares on each of January 7, 2020, January 7, 2021, and January 7, 2022. This grant is subject to an accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.